[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  WhatMarketMinds [@WhatMarketMind](/creator/twitter/WhatMarketMind) on x 1098 followers Created: 2025-07-17 13:29:15 UTC $ACBr 20250710-Goldman Sachs-Alpha Bank (ACBr) 2Q25 preview $AMPF 20250710-Goldman Sachs-Amplifon (AMPF) Updating estimates prior to Q2 results $AMLX 20250710-Goldman Sachs-Amylyx Pharmaceuticals Inc. (AMLX) Potential blockbuster opportunity for av $BNPP 20250710-Goldman Sachs-BNP Paribas (BNPP) Q2’25 Preview $DOCS 20250710-Goldman Sachs-Dr. Martens Plc (DOCS) ： AGM Trading Update _On track and FY26 outlook uncha $GERN 20250710-Goldman Sachs-Geron Corp. (GERN) Commercial challenges to persist near_term； Resume at Se $ICAD 20250710-Goldman Sachs-Icade (ICAD) Vacancy rates to edge up on upcoming lease expiries； downgrade $LLOY 20250710-Goldman Sachs-Lloyds Banking Group (LLOY) Q2’25 Preview $NBIX 20250710-Goldman Sachs-Neurocrine Biosciences Inc. (NBIX) Attractive growth profile bolstered by $7201 20250710-Goldman Sachs-Nissan Motor (7201) Lowering our target price to ￥310 from ￥350 to reflect $NDXG 20250710-Goldman Sachs-Nordex SE (NDXG) ： Strong Q2 order intake points to order growth in FY 2025 $G24n 20250710-Goldman Sachs-Scout24 SE (G24n) 2Q25 preview： Strong momentum to continue with slight ma $SSE 20250710-Goldman Sachs-SSE Plc (SSE) ： Regulatory clarity on national pricing a positive $SNDX 20250710-Goldman Sachs-Syndax Pharmaceuticals Inc. (SNDX) Attractive near_term leukemia launch wit $ABBV 20250710-J.P. Morgan-AbbVie (ABBV) 2Q Preview： SkyriziRinvoq Continue To Trend Ahead Of Expectatio $ADP 20250710-J.P. Morgan-Aeroports de Paris (ADP) Expect H1 EBITDA to be up 13％ yy； see potential ups $AMBER 20250710-J.P. Morgan-Amber Enterprises (AMBER) Looking to raise Rs25bn_could be for PCB capex or M& $138930 20250710-J.P. Morgan-BNK Financial Group (138930) 2Q results to beat Street estimates with reduced cre $BMY 20250710-J.P. Morgan-Bristol_Myers Squibb Company (BMY) 2Q25 Preview–See Results Modestly Ahead， Co $CPRI 20250710-J.P. Morgan-Davide Campari_Milano NV (CPRI) Q225 Preview：Top_line to improve aided by phas $DHER 20250710-J.P. Morgan-Delivery Hero SE (DHER) All eyes on Asia _ We're assuming a GMV decline of _ $HWDN 20250710-J.P. Morgan-Howden Joinery Group Plc (HWDN) H125 Preview； expect broadly flat operating pro $139130 20250710-J.P. Morgan-iM Financial Group (139130) Normalizing earnings with manageable credit costs； PT $9526 20250710-J.P. Morgan-Jahez (9526) ：Snoonu acquisition reinforces growth ambitions $323410 20250710-J.P. Morgan-Kakao Bank (323410) Likely in_line 2Q results， but increasing operating challeng $PEP 20250710-J.P. Morgan-PepsiCo (PEP) Soft Trends Continue； Bar Is Low， but Lack of Catalysts Near Ter $PM 20250710-J.P. Morgan-Philip Morris International (PM) Q225 Preview： Strong momentum to continue $RRTL 20250710-J.P. Morgan-RTL (RRTL) SkyD_a “hard boiled frog” that may give RTL years of indigestion. D $SRPT 20250710-J.P. Morgan-Sarepta Therapeutics (SRPT) Why We Remain Overweight ... $SOFI 20250710-J.P. Morgan-SoFi (SOFI) A Big， Beautiful Opportunity for Private Student Loan Lenders $APAM 20250710-Jefferies-Aperam (APAM) Downgrading APAM to Hold on Weak EU Pricing and Relatively Less US $HTWS 20250710-Jefferies-Helios Towers (HTWS) 1H25 Results Due Before Open on 31st July $WIZZ 20250710-Jefferies-Wizz Air (WIZZ) Q1 Preview： Good Easter， But Yield and Disruption Pressure Airli $ABNd 20250710-UBS-ABN AMRO (ABNd) The ABN 'box set'： A multiyear re_rating story. Episode X _ Profitabl $GSK 20250710-UBS-GSK (GSK) 2Q25 Results Preview $IPN 20250710-UBS-Ipsen SA (IPN) Q2'25 results preview _ Iqirvo time $ITUB4 20250710-UBS-Itau Unibanco (ITUB4) Steady performer， but already priced in； downgrade to Neutral $JD (JD) 2Q25 preview； Factoring in additional food delivery investments $6990 20250710-UBS-Kelun Biotech (6990) sac_TMT to gain a meaningful share of a US$25bn opportunity $LONN 20250710-UBS-Lonza Group AG (LONN) A reliable compounder in an uncertain environment $SQN 20250710-UBS-Swissquote Group Holding SA (SQN) Updating forecasts for Yuh， rates and trading trends $000100 20250710-UBS-TCL Tech (000100) PV business drags on Q225 profit， while core panel business remains $TRNT 20250710-UBS-Trainline PLC (TRNT) UK June rail volumes show sustained strength  XXX engagements  **Related Topics** [$bnpp](/topic/$bnpp) [$amlx](/topic/$amlx) [$ampf](/topic/$ampf) [$acbr](/topic/$acbr) [$docs](/topic/$docs) [Post Link](https://x.com/WhatMarketMind/status/1945838208459374934)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
WhatMarketMinds @WhatMarketMind on x 1098 followers
Created: 2025-07-17 13:29:15 UTC
$ACBr 20250710-Goldman Sachs-Alpha Bank (ACBr) 2Q25 preview $AMPF 20250710-Goldman Sachs-Amplifon (AMPF) Updating estimates prior to Q2 results $AMLX 20250710-Goldman Sachs-Amylyx Pharmaceuticals Inc. (AMLX) Potential blockbuster opportunity for av $BNPP 20250710-Goldman Sachs-BNP Paribas (BNPP) Q2’25 Preview $DOCS 20250710-Goldman Sachs-Dr. Martens Plc (DOCS) ： AGM Trading Update _On track and FY26 outlook uncha $GERN 20250710-Goldman Sachs-Geron Corp. (GERN) Commercial challenges to persist near_term； Resume at Se $ICAD 20250710-Goldman Sachs-Icade (ICAD) Vacancy rates to edge up on upcoming lease expiries； downgrade $LLOY 20250710-Goldman Sachs-Lloyds Banking Group (LLOY) Q2’25 Preview $NBIX 20250710-Goldman Sachs-Neurocrine Biosciences Inc. (NBIX) Attractive growth profile bolstered by $7201 20250710-Goldman Sachs-Nissan Motor (7201) Lowering our target price to ￥310 from ￥350 to reflect $NDXG 20250710-Goldman Sachs-Nordex SE (NDXG) ： Strong Q2 order intake points to order growth in FY 2025 $G24n 20250710-Goldman Sachs-Scout24 SE (G24n) 2Q25 preview： Strong momentum to continue with slight ma $SSE 20250710-Goldman Sachs-SSE Plc (SSE) ： Regulatory clarity on national pricing a positive $SNDX 20250710-Goldman Sachs-Syndax Pharmaceuticals Inc. (SNDX) Attractive near_term leukemia launch wit $ABBV 20250710-J.P. Morgan-AbbVie (ABBV) 2Q Preview： SkyriziRinvoq Continue To Trend Ahead Of Expectatio $ADP 20250710-J.P. Morgan-Aeroports de Paris (ADP) Expect H1 EBITDA to be up 13％ yy； see potential ups $AMBER 20250710-J.P. Morgan-Amber Enterprises (AMBER) Looking to raise Rs25bn_could be for PCB capex or M& $138930 20250710-J.P. Morgan-BNK Financial Group (138930) 2Q results to beat Street estimates with reduced cre $BMY 20250710-J.P. Morgan-Bristol_Myers Squibb Company (BMY) 2Q25 Preview–See Results Modestly Ahead， Co $CPRI 20250710-J.P. Morgan-Davide Campari_Milano NV (CPRI) Q225 Preview：Top_line to improve aided by phas $DHER 20250710-J.P. Morgan-Delivery Hero SE (DHER) All eyes on Asia _ We're assuming a GMV decline of _ $HWDN 20250710-J.P. Morgan-Howden Joinery Group Plc (HWDN) H125 Preview； expect broadly flat operating pro $139130 20250710-J.P. Morgan-iM Financial Group (139130) Normalizing earnings with manageable credit costs； PT $9526 20250710-J.P. Morgan-Jahez (9526) ：Snoonu acquisition reinforces growth ambitions $323410 20250710-J.P. Morgan-Kakao Bank (323410) Likely in_line 2Q results， but increasing operating challeng $PEP 20250710-J.P. Morgan-PepsiCo (PEP) Soft Trends Continue； Bar Is Low， but Lack of Catalysts Near Ter $PM 20250710-J.P. Morgan-Philip Morris International (PM) Q225 Preview： Strong momentum to continue $RRTL 20250710-J.P. Morgan-RTL (RRTL) SkyD_a “hard boiled frog” that may give RTL years of indigestion. D $SRPT 20250710-J.P. Morgan-Sarepta Therapeutics (SRPT) Why We Remain Overweight ... $SOFI 20250710-J.P. Morgan-SoFi (SOFI) A Big， Beautiful Opportunity for Private Student Loan Lenders $APAM 20250710-Jefferies-Aperam (APAM) Downgrading APAM to Hold on Weak EU Pricing and Relatively Less US $HTWS 20250710-Jefferies-Helios Towers (HTWS) 1H25 Results Due Before Open on 31st July $WIZZ 20250710-Jefferies-Wizz Air (WIZZ) Q1 Preview： Good Easter， But Yield and Disruption Pressure Airli $ABNd 20250710-UBS-ABN AMRO (ABNd) The ABN 'box set'： A multiyear re_rating story. Episode X _ Profitabl $GSK 20250710-UBS-GSK (GSK) 2Q25 Results Preview $IPN 20250710-UBS-Ipsen SA (IPN) Q2'25 results preview _ Iqirvo time $ITUB4 20250710-UBS-Itau Unibanco (ITUB4) Steady performer， but already priced in； downgrade to Neutral $JD (JD) 2Q25 preview； Factoring in additional food delivery investments $6990 20250710-UBS-Kelun Biotech (6990) sac_TMT to gain a meaningful share of a US$25bn opportunity $LONN 20250710-UBS-Lonza Group AG (LONN) A reliable compounder in an uncertain environment $SQN 20250710-UBS-Swissquote Group Holding SA (SQN) Updating forecasts for Yuh， rates and trading trends $000100 20250710-UBS-TCL Tech (000100) PV business drags on Q225 profit， while core panel business remains $TRNT 20250710-UBS-Trainline PLC (TRNT) UK June rail volumes show sustained strength
XXX engagements
